APOL1-Associated End-Stage Renal Disease in a Living Kidney Transplant Donor

American Journal of Transplantation

Volumn 16, Issue 12, 2016, Pages 3568-3572

  Zwang, N A ^a,b   Shetty, A ^a   Sustento Reodica, N ^a   Gordon, E J ^a   Leventhal, J ^a   Gallon, L ^a   Friedewald, J J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

clinical research practice; donor nephrectomy; donors and donation: donor follow up; donors and donation: living; kidney transplantation nephrology; organ transplantation in general; pathology histopathology

Indexed keywords

ALBUMIN; ALEMTUZUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINUCLEAR ANTIBODY; APOLIPOPROTEIN; APOLIPOPROTEIN L1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CONTRAST MEDIUM; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FILGRASTIM; IBUPROFEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; BODY MASS; CASE REPORT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FACE EDEMA; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GLOMERULOSCLEROSIS; HEMODIALYSIS; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY HYPERTROPHY; KIDNEY SIZE; KIDNEY TRANSPLANTATION; LABORATORY TEST; LAPAROSCOPIC SURGERY; LEG SWELLING; LEUKAPHERESIS; LIVING DONOR; MALE; METALLIC TASTE; MIDDLE AGED; NEPHRECTOMY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; URINE VOLUME; AFRICAN AMERICAN; CHRONIC KIDNEY FAILURE; GENETIC VARIATION; GENETICS; GENOTYPE; GLOMERULUS FILTRATION RATE; HOMOZYGOTE; KIDNEY FUNCTION TEST; METABOLISM; PATHOLOGY; PROGNOSIS; RISK FACTOR; TRANSPLANTATION;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEIN L1; BIOMARKERS; FEMALE; GENETIC VARIATION; GENOTYPE; GLOMERULAR FILTRATION RATE; HOMOZYGOTE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; PROGNOSIS; RISK FACTORS; TISSUE AND ORGAN HARVESTING;

EID: 84990943429     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14035     Document Type: Article

References (24)

1. Saxena AB, Busque S, Arjane P, Myers BD, Tan JC. Preoperative renal volumes as a predictor of graft function in living donor transplantation. Am J Kidney Dis 2004; 44: 877–885.
2. Giral M, Nguyen JM, Karam G, et al. Impact of graft mass on the clinical outcome of kidney transplants. J Am Soc Nephrol 2005; 16: 261–268.
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293–1298.
4. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841–845.
5. Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013; 83: 114–120.
6. Foster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013; 24: 1484–1491.
7. Freedman BI, Langefeld CD, Turner J, et al. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 2012; 82: 805–811.
8. Grams ME, Sang Y, Levey AS, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med 2016; 374: 411–421.
9. Gaber LW, Moore LW, Alloway RR, Flax S, Gaber AO. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection. Transpl Proc 1995; 27: 1019.
10. Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363: 724–732.
11. Cohen DM, Mittalhenkle A, Scott DL, Young CJ, Norman DJ. African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation 2011; 92: 722–725.
12. Riella LV, Sheridan AM. Testing for high-risk APOL1 alleles in potential living kidney donors. Am J Kidney Dis 2015; 66: 396–401.
13. Gordon EJ, Friedewald JJ. A genetic test could predict future troubles for kidney donors—Why not use it? The Conversation. [cited 2015 Oct 2]. Available from: http://theconversation.com/a-genetic-test-could-predict-future-troubles-for-kidney-donors-why-not-use-it-48077.
14. Cameron LD, Muller C. Psychosocial aspects of genetic testing. Curr Opin Psychiatry 2009; 22: 218–223.
15. Christensen KD, Roberts JS, Zikmund-Fisher BJ, et al. Associations between self-referral and health behavior responses to genetic risk information. Genome Med 2015; 7: 10.
16. Kofman T, Audard V, Narjoz C, et al. APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Am J Kidney Dis 2014; 63: 816–819.
17. Lee BT, Kumar V, Williams TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12: 1924–1928.
18. Reeves-Daniel AM, DePalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11: 1025–1030.
19. Freedman BI, Julian BA, Pastan SO, et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant 2015; 15: 1615–1622.
20. Freedman BI, Pastan SO, Israni AK, et al. APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 2016; 100: 194–202.
21. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22: 2119–2128.
22. Ma L, Shelness GS, Snipes JA, et al. Localization of APOL1 protein and mRNA in the human kidney: Nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol 2015; 26: 339–348.
23. Kruzel-Davila E, Wasser WG, Aviram S, Skorecki K. APOL1 nephropathy: From gene to mechanisms of kidney injury. Nephrol Dial Transplant 2016; 31: 349–358.
24. Olabisi OA, Zhang JY, VerPlank L, et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci USA 2016; 113: 830–837.